Dealpolitik: Showdown Looms Between Glaxo and Human Genome Sciences – Deal Journal – WSJ

Dealpolitik: Showdown Looms Between Glaxo and Human Genome Sciences – Deal Journal – WSJ.

Nader Nazemi

On Friday, Human Genome Sciences told GlaxoSmithKline that it should submit a “final bid” for HGS by July 16. GSK is making a tender offer directly to HGS shareholders to buy HGS for $13 per share. HGS has rejected that bid as too low and has vowed to seek alternatives.

Nader Nazemi

HGS’ headquarters in Rockville, Maryland

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s